| Citation: |
Managment of Bone Lose in Patients with Breast Cancer[J]. Cancer Research on Prevention and Treatment, 2012, 39(06): 619-622. DOI: 10.3971/j.issn.1000-8578.2012.06.002
|
| [1] |
National Institutes of Health.Osteoporosis prevention，diagnosis and therapy[J].NIH Consens Statement，2000,17(1):1-45.
|
| [2] |
Reid DM,Doughty J,Eastell R,et al.Guidance for the management of breast cancer treatment-induced bone loss:a consensus position statement from a UK Expert Group[J].Cancer Treat Rev，2008，34 Suppl 1：S3-S18.
|
| [3] |
Poór G，Atkinson EJ，O′Fallon WM，et al.Determinants of reduced survival following hip fractures in men[J].Clin Orthop Relat Res,1995,(319):260-5.
|
| [4] |
Mao GQ,Sun YM,Yang T,et al.A survery of in-patient hospital care in patients with osteoporotic hip fracture[J].Zhongguo Gu Zhi Shu Song Za Zhi,2011,17(10):881-3.[毛国庆，孙玉明，杨挺，等.骨质疏松性髋部骨折住院治疗情况分析[J].中国骨质疏松杂志，2011，17（10）：881-3.]
|
| [5] |
World Health Organization.Assessment of fracture risk and its application to screening for postmenopausal osteoporosis.Report of a WHO study group[J].World Health Organ Tech Rep Ser，1994,843:1-129.
|
| [6] |
Kanis JA.Assessment of fracture risk and its application to screening for postmenopausal osteoporosis:synopsis of a WHO report.WHO Study Group[J].Osteoporosis Int,1994,4(6):368-81.
|
| [7] |
Fogelman I,Blake GM,Blamey R,et al.Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide，methotrexate and 5-fluorouracil(CMF)[J].Osteoporos Int,2003,14(12):1001-6.
|
| [8] |
Headley JA，Theriault RL，LeBlanc AD，et al.Pilot study of bone mineral density in breast cancer patients treated with adjuvant chemotherapy[J].Cancer Invest,1998,16(1):6-11.
|
| [9] |
Vehmanen L，Elomaa I，Blomqvist C，et al.Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status[J].J Clin Oncol,2006,24(4):675-80.
|
| [10] |
Grey AB，Stapleton JP，Evans MC，et al.The effect of the antiestrogen tamoxifen on bone mineral density in normal late postmenopausal women[J].Am J Med，1995,99(6):636-41.
|
| [11] |
Cuzick J，Sestak I，Baum M,et al，Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer:10-year analysis of the ATAC trial[J].Lancet Oncol，2010,11(2):1135-41.
|
| [12] |
Eastell R，Adams J，Clack G,et al.Long-term effects of anast rozole on bone mineral density:7-year results from the ATAC trial[J].Ann Oncol，2011，22(4):857-62.
|
| [13] |
Coates AS，Keshaviah A，Thürlimann B，et al.Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer:update of study BIG 1-98[J].J Clin Oncol,2007,25(5):486-92.
|
| [14] |
Coombes RC，Kilburn LS，Snowdon CF，et al.Survival and safety of exemestane versus tamoxifen after 2-3 years′ tamoxifen treatment (Intergroup Exemestane Study):a randomised controlled trial[J].Lancet,2007,369(9561):559-70.
|
| [15] |
Van Poznak C，Hannon RA，Mackey JR，et al.Prevention of aromatase inhibitor-induced bone loss using risedronate:the SABRE trial[J].J Clin Oncol,2010,28(6):967-75.
|
| [16] |
Lester JE，Dodwell D，Purohit OP，et al.Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer[J].Clin Cancer Res,2008,14(19):6336-42.
|
| [17] |
Gnant M，Mlineritsch B，Stoeger H，et al.Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer:62-month follow-up from the ABCSG-12 randomised trial[J].Lancet Oncol，2011,12（7）：631-41.
|
| [18] |
Llombart A，Frassoldati A，Paija O，et al.Immediate administration of zoledronic acid reduces aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer:12-month analysis of the E-ZO-FAST trial[J].Clin Breast Cancer,2012,12(1):40-8.
|
| [19] |
Van Poznak CH，Temin S,Yee GC,et al.American society of clinical oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer[J].Clin Oncol,2011,29(9):1221-7.
|
| [20] |
Hillner BE，Ingle JN，Chlebowski RT,et al.American society of clinical oncology 2003 update on the role of bisphosphonates and bone health issues in breast cancer[J].J Clin Oncol,2003,21(21):4042-57.
|
| [21] |
Hadji P，Body JJ，Aapro MS,et al，Practical guidance for the management of aromatase inhibitor- associated bone loss[J].Ann Oncol，2008,19(8):1407-16.
|
| [22] |
Hadji P，Aapro MS，Body JJ,et al，Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer:practical guidance for prevention and treatment[J].Ann Oncol,2011,22(12):2546-55.
|
| [23] |
Delmas PD.Markers of bone turnover for monitoring treatment of osteoporosis with antiresorptive drugs[J].Osteoporos Int,2000,11 Suppl 6:S66-76.
|
| [24] |
Eastell R.Treatment of postmenopausal osteoporosis[J].N Engl J Med,1998,338(11):736-46.
|
| [25] |
Brufsky A，Harker WG，Beck JT，et al.Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer[J].J Clin Oncol,2007,25(7):829-36.
|
| [1] | WU Wenbo, DUAN Guochen. Clinical Research Progress of Double Primary Cancers of Breast and Lung with Breast Cancer as the First Primary Cancer[J]. Cancer Research on Prevention and Treatment, 2021, 48(4): 400-405. DOI: 10.3971/j.issn.1000-8578.2021.20.1033 |
| [2] | HE Mingyuan, LI Fenghu, CHANG Jianying, LI Jiehui, WANG He'ran, SONG Yang, LIU Liyang, RAN Li. Correlation of Serum Alkaline Phosphatase and Lactate Dehydrogenase with Survival of Stage Ⅰ-Ⅲ Breast Cancer Patients[J]. Cancer Research on Prevention and Treatment, 2017, 44(12): 816-822. DOI: 10.3971/j.issn.1000-8578.2017.17.0544 |
| [3] | LV Minhao, QIN Li, LI Juntao, GUO Xuhui, LIU Fawen, CUI Shude, ZHANG Hengwei. 原发性乳腺癌分子分型与新辅助化疗疗效及预后的相关性[J]. Cancer Research on Prevention and Treatment, 2015, 42(08): 782-788. DOI: 10.3971/j.issn.1000-8578.2015.08.007 |
| [4] | SUN Qitian, GAO Yu, LIU Xiaoyan, HE Xiaolei, XING Enhong, SUN Lixin. Effects of High Glucose and High Insulin on Adenosine Monophosphate-activated Protein Kinase Expression in Breast Cancer Cells MCF-7 and Metformin Intervention[J]. Cancer Research on Prevention and Treatment, 2015, 42(04): 328-333. DOI: 10.3971/j.issn.1000-8578.2015.04.003 |
| [5] | ZHANG Qiang, MA Hesuti, BAI Qiang, YANG Zhigang, HUO Richa. Effects of Ibandronic Acid Sodium on Bone Mineral Density of Prostate Cancer Patients with Bone Metastasis after Androgen Deprivation Therapy[J]. Cancer Research on Prevention and Treatment, 2014, 41(02): 131-133. DOI: 10.3971/j.issn.1000-8578.2014.02.009 |
| [6] | Zhou Xin, Wu Chengyi. Relationship of CD44＋/CD24－/low with Responsiveness of Breast Cancer to Anthracycline-based Chemotherapy[J]. Cancer Research on Prevention and Treatment, 2012, 39(08): 966-969. DOI: 10.3971/j.issn.1000-8578.2012.08.021 |
| [7] | Ding Xiaoyan, Fan Ying, Ma Fei, Li Qing, Wang Jiayu, Yuan Peng, Zhang Pin, Xu Binghe. Analyses on Skeletal-related Events and Prognosis of Postmenopausal Breast Cancer Patients with Bone Metastasis[J]. Cancer Research on Prevention and Treatment, 2012, 39(06): 627-631. DOI: 10.3971/j.issn.1000-8578.2012.06.004 |
| [8] | WEI Ling, SONG Xian-rang, SUN Ju-jie, ZHENG Ai-qing, WANG Xing-wu, XIE Li, LI Min, ZUO Wen-shu. Effects of TK Adenovirus Vector Regulated by Hypoxia and Radiation Combined with Radiotherapy on Growth of Transplanted Tumors of Breast Cancer in Nude Mice[J]. Cancer Research on Prevention and Treatment, 2010, 37(03): 259-262. DOI: 10.3971/j.issn.1000-8578.2010.03.004 |
| [9] | YANG Guang, ZHANG Xiang-hong, WANG Xiao-ling, ZHAO Jun-jing, ZHANG Zhi-gang, YAN Xia, WANG Jun-ling. Expression and Clinicopathlogic Significance of OPN and ON in Breast Carcinoma[J]. Cancer Research on Prevention and Treatment, 2006, 33(09): 653-655，. DOI: 10.3971/j.issn.1000-8578.1321 |
| [10] | Luo Zhensheng, . The Analysis Report of 12 Cases Double-side Primary Breast Cancer[J]. Cancer Research on Prevention and Treatment, 1997, 24(3): 180-182. |
This work is licensed under a Creative Commons Attribution 3.0 License.
Copyright © Editorial Department of Cancer Prevention Research 鄂公网安备 42011102005013号 鄂ICP备2022015867号
Supported by: Beijing Renhe Information Technology Co., Ltd. 
DownLoad: